REGULUS THERAPEUTICS INC (RGLS)
US75915K3095 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 29.59M | 23.77M | 24.20M | 60.40M | 31.10M | |||
| Marketable Securities | 67.97M | 0.00 | 14.90M | N/A | N/A | |||
| Receivables | N/A | N/A | N/A | 0.00 | 500.00K | |||
| Other Current Assets | 3.89M | 4.41M | 5.00M | 4.90M | 5.10M | |||
| Total Current Assets | 101.45M | 28.18M | 44.10M | 65.20M | 36.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 2.42M | 2.54M | 2.60M | 2.80M | 500.00K | |||
| Investments And Advances | 10.17M | N/A | N/A | N/A | N/A | |||
| Intangibles | 30.00K | 33.00K | 100.00K | 100.00K | 100.00K | |||
| Other Non-Current Assets | 74.00K | N/A | 0.00 | 300.00K | 300.00K | |||
| Total Non-Current Assets | 12.69M | 2.57M | 2.60M | 3.30M | 900.00K | |||
| TOTAL ASSETS | 114.14M | 30.75M | 46.70M | 68.50M | 37.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 540.00K | 1.33M | 4.50M | 0.00 | 4.70M | |||
| Accrued Expenses | 2.49M | 4.59M | 4.40M | 3.60M | 3.40M | |||
| Accounts Payable | 406.00K | 204.00K | 200.00K | 300.00K | 500.00K | |||
| Other Current Liabilities | 2.25M | 2.38M | 2.60M | 1.30M | 3.00M | |||
| Total Current Liabilities | 5.68M | 8.51M | 11.70M | 5.20M | 11.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 4.70M | 0.00 | |||
| Other Non-Current Liabilities | 868.00K | 1.05M | 1.80M | 3.60M | 0.00 | |||
| Total Non-Current Liabilities | 868.00K | 1.05M | 1.70M | 8.30M | 0.00 | |||
| TOTAL LIABILITIES | 6.55M | 9.56M | 13.40M | 13.50M | 11.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -521.68M | -513.21M | -483.20M | -454.90M | -427.00M | |||
| Additional Paid In Capital | 629.25M | 534.38M | 516.50M | 509.70M | 453.00M | |||
| Common Shares | 70.00K | 25.00K | 0.00 | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -45.00K | 0.00 | 0.00 | N/A | N/A | |||
| Shares Outstanding | 65.47M | 20.22M | 16.80M | 14.60M | 6.70M | |||
| Tangible Book Value per Share | 1.64 | 1.05 | 1.98 | 3.76 | 3.87 | |||
| Total Shareholders' Equity | 107.59M | 21.19M | 33.30M | 55.00M | 26.00M | |||
| TOTAL LIABILITIES AND EQUITY | 114.14M | 30.75M | 46.70M | 68.50M | 37.60M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.09 | N/A | |||
| Current Ratio | 17.85 | 3.31 | 3.77 | 12.54 | 3.16 | |||
| Return On Assets (ROA) | -27.48% | -97.68% | -60.64% | -40.60% | -41.84% | |||
| Return On Equity (ROE) | -29.15% | -141.77% | -85.05% | -50.56% | -60.50% | |||
All data in USD